PHYSICIAN SCIENTIST TRAINING GRANT IN ONCOLOGY
PHYSICIAN SCIENTIST TRAINING GRANT IN ONCOLOGY
批准号:
6375471
负责人:
CHRIS H. TAKIMOTO
金额:
$42.47万
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
已结题
起止时间:
1992-09-05 至 2003-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Many institutions can train outstanding clinical oncologists,
however, few institutions contain the necessary elements required
to train these young clinicians for a career in investigation. San
Antonio has a long history of boil basic and clinical cancer
research and has developed major expertise in cooperative group
trials, investigational drug development, breast cancer research,
and bone marrow transplant. To obtain excellence in these areas,
basic and clinical investigators have worked closely together.
Recently, through the joint efforts of the University of Texas
Health Science Center (UTHSCSA) and the Cancer Therapy and Research
Center (CTRC), the cancer research efforts have been organized into
San Antonio Cancer Institute (SACI), an NCI designated comprehensive
cancer center. As described in this application, San Antonio can
provide trainees with appropriate research experience, didactic
instruction, and mentoring to begin a career in clinical cancer
research. Our program will identify physician candidate trainees
from medical, surgical, and radiation oncology. An Advisory
Committee composed of key members of SACI and the clinical chairs
of UTHSCSA will provide oversight for the training program. Trainees
will be supported for two years on this training grant. Each trainee
will select a SACI member as a mentor for their training in
laboratory research skills. Once selected, Research Committee will
be formed to provide detailed oversight of the trainee's progress.
At the end of the first year of research support, the trainee will
submit a clinical investigation proposal. The proposal will be
designed to generate sufficient data to launch their research
career. At the end of two years of support, th trainee will return
to their clinical department as junior faculty members to continue
their career development. Thus, this training program will allow
young clinicians to develop an area of research expertise and bring
this expertise back to their "home" clinical department.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay.
基于新的生物素化培养地扩展测定法,用于研究端粒酶抑制剂的人类乳腺癌模型。
DOI:
10.1038/sj.bjc.6690526
发表时间:
1999-07
期刊:
BRITISH JOURNAL OF CANCER
影响因子:
8.8
作者:
[Raymond, E, Sun, D, Izbicka, E, Mangold, G, Silvas, E, Windle, B, Sharma, S, Soda, H, Laurence, R, Davidson, K, Von Hoff, DD]
通讯作者:
Von Hoff, DD
Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line.
二甲亚砜 (DMSO) 可逆性抑制伯基特淋巴瘤细胞系中的端粒酶活性。
DOI:
10.1016/s0145-2126(97)00188-4
发表时间:
1998
期刊:
Leukemia research
影响因子:
2.7
作者:
[Sharma,S, Raymond,E, Soda,H, Izbicka,E, Davidson,K, Lawrence,R, VonHoff,DD]
通讯作者:
VonHoff,DD
DOI:
10.1182/blood.v87.4.1495.bloodjournal8741495
发表时间:
1996-02-15
期刊:
BLOOD
影响因子:
20.3
作者:
[Alsina, M, Boyce, B, Roodman, GD]
通讯作者:
Roodman, GD
An in vivo model of human multiple myeloma bone disease.
人类多发性骨髓瘤骨病的体内模型。
DOI:
--
发表时间:
1995
期刊:
Stem cells (Dayton, Ohio)
影响因子:
--
作者:
[Alsina,M, Boyce,BF, Mundy,GR, Roodman,GD]
通讯作者:
Roodman,GD
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer.
氟他胺作为晚期胰腺癌患者二线化疗的 II 期研究。
DOI:
10.1023/a:1005989519350
发表时间:
1997
期刊:
Investigational new drugs
影响因子:
3.4
作者:
[Sharma,JJ, Razvillas,B, Stephens,CD, Hilsenbeck,SG, Sharma,A, Rothenberg,ML]
通讯作者:
Rothenberg,ML
共 8 条
PH I STUDY OF BMS-247550 GIVEN ON CONTINUOUS WEEKLY SCHEDULE IN PTS W/ADV MALIG
-
批准号:7378182
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2006
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
PH I PK STUDY OF PS341 IN PTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION
-
批准号:7204786
-
项目类别:
-
资助金额:$0.48万
-
财政年份:2005
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
PH I STUDY OF BMS-247550 GIVEN ON CONTINUOUS WEEKLY SCHEDULE IN PTS W/ADV MALIG
-
批准号:7204785
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2005
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
Ph I Pharmacokinetics of STI571 in Cancer & Liver Dis
-
批准号:6972381
-
项目类别:
-
资助金额:$1.05万
-
财政年份:2004
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
Ph I Pharmacokinetics of STI571 in Neoplasms/kidney Dis
-
批准号:6972382
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2004
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
ERBB1 AND ERBB2 BLOCKADE IN ADVANCED BREAST CANCER
-
批准号:6867516
-
项目类别:
-
资助金额:$26.41万
-
财政年份:2002
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
PHARMACOLOGIC AND PHASE I STUDIES OF NEW AGENTS FOR THE TREATMENT OF SOLID TUMORS
-
批准号:6123768
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
Preclinical & clinical pharmacology of agents in GI malignancies: topoisomerase I
-
批准号:6312281
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
PRECLINICAL AND CLINICAL PHARMACOLOGY OF PROMISING AGENTS IN GI MALIGNANCIES
-
批准号:6123767
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
PHARMACOLOGIC AND PHASE I STUDIES OF NEW AGENTS FOR THE TREATMENT OF HUMAN SOLID
-
批准号:6290856
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:CHRIS H. TAKIMOTO
-
依托单位:
海外基金